



File No. BIO/CT/23/000107

Dated 20-08-2024

To

M/s. CuraTeQ Biologics Private Limited
Galaxy, Floors: 22-24, Plot No. 1, Survey No: 83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Ranga Reddy District,
Hyderabad- 500032, Telangana, India.

Subject: Application for grant of permission to conduct Phase I Clinical trial titled –"A randomized phase 1, double-blind, single dose, three-arm, parallel group comparative Pharmacokinetic, Pharmacodynamic, safety, and immunogenicity assessment of BP08 (Tocilizumab) versus US licensed Actemra® and EU approved RoActemra® administration through the Intravenous infusion route in healthy adult male subjects" vide sponsor protocol no BP08-101; Version No. 01 dated 16.08.2023 – regarding.

Ref.: Your Application No BIO/CT04/FF/2023/39220 dated 18-08-2023.

Sir,

With reference to your Application No. BIO/CT04/FF/2023/39220 dated 18-08-2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019. Further the Insurance certificate mentioning the protocol number and number of subjects should be submitted to CDSCO before initiating the trial.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified.
- (XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.
- (XIX) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of two years from the date of its issue, unless extended by the Central Licencing Authority.
- (XX) The firm should submit Clinical study report (CSR) to this office after completion of trial.

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORIGINATOR, c=IN, ou=CENTRAL DRUGS STANDARD
CONTROL, email=rajeev.singh@cdsc.gov.in,
2.5.4.20=42d7189b1c0981bb5a2634a73d025f4b11b680,
a91f0877348040a43ee361b, postalCode=110002,
st=Delhi,
serialNumber=657f5e47d940985d8f03bdc902d0e1fe73cfa
12a1a126ea94f5701124a19013, cn=RAJEEV SINGH
RAGHUVANSHI
Date: 2024.08.20 15:40:34 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

The Central Licencing Authority hereby permits **M/s. CuraTeQ Biologics Private Limited, Galaxy Floors: 22-24, Plot No. 1, Survey No: 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad-500032, Telangana, India** to conduct clinical trial of the new drug or investigational new drug study titled "A randomized phase 1, double-blind, single dose, three-arm, parallel group comparative Pharmacokinetic, Pharmacodynamic, safety, and immunogenicity assessment of BP08 (Tocilizumab) versus US licensed Actemra® and EU approved RoActemra® administration through the Intravenous infusion route in healthy adult male subjects" vide sponsor protocol no BP08-101; Version No. 01 dated 16.08.2023 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 20.08.2024

**RAJEEV SINGH
RAGHUVANSHI**

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD
CONTROL ORGANISATION,
2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11
b680a91f08773480400a43ee361b,
postalCode=110002, st=Delhi,
serialNumber=657f5e47d940985d8f03bdc902d0e1f
e73cfa12a1a126ea94fa5701124a19013, cn=RAJEEV
SINGH RAGHUVANSHI
Date: 2024.08.20 15:41:11 +05'30'

Annexure:**Details of new drug or investigational new drug:**

Name of the new drug or investigational new drug	Tocilizumab Concentrate for solution for infusion 20mg/mL		
Therapeutic class	Immunosuppresant		
Dosage form:	Concentrate for solution for infusion in 20mL vial Each 20 mL vial contains 400 mg Tocilizumab (20mg/vial)		
Composition:	Ingredient	Function	Qty/Vial (mg)
	Tocilizumab IH	Active ingredient	400 mg
	Disodium phosphate dodecahydrate Ph.Eur.	Buffering agent	27.2 mg
	Sodium dihydrogen phosphate dihydrate Ph.Eur.	Buffering agent	34.6 mg
	Polysorbate 80 JP, Ph.Eur., NF	Stabilizer	10 mg
	Sucrose NF, Ph.Eur., JP, ChP	Stabilizer	1000 mg
	Water for injection IP, Ph.Eur., BP and USP	Vehicle	q.s. to 20 mL
Indications:	Rheumatoid Arthritis		

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Veeda Clinical Research Ltd. 1 st, 2nd, 3rd & 4th Floor VEDANT Complex, Nr. Y.M.C.A. Club, S. G. Highway Road, Vejalpur, Ahmedabad 380 051, Gujarat, India	Sangini Hospital Ethics Committee, Sangini Hospital, Santorini Square, B/H Abhishree Complex Opp. Star Bazar Nr Jodhpur Cross Roads Satellite Ahmedabad Gujarat – 380015 India <u>EC Reg. No.</u> ECR/147/inst/GJ/2013/RR-19.	Dr. Darshankumar Kharadi